home / stock / sgen / sgen articles
Seagen (NASDAQ:SGEN) has outperformed the market over the past 15 years by 11.59% on an annualized basis producing an average annual return of 22.4...
Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 15.19% on an annualized basis producing an average annual return of 24.8%...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Seagen (NASDAQ:SGEN) has outperformed the market over the past 15 years by 11.54% on an annualized basis producing an average annual return of 20.9...
Nurix Therapeutics Inc (NASDAQ: NRIX) has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc ...
RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a price target of...
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurren...
News, Short Squeeze, Breakout and More Instantly...